Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
- Create Cross-Bureau Scheme at MHLW to Fuel Rx-to-OTC Switches: Regulatory Reform Panel
July 6, 2020
- MHLW Donates Nearly 200 Million Yen to GARDP to Combat Antimicrobial Resistance
July 6, 2020
- Key MOF Panel Passes on Typical Budget Recommendation amid COVID-19
July 3, 2020
- Ruling Parties Call for Careful Discussions on Off-Year Drug Re-Pricing
July 3, 2020
- MHLW to Report Approval Plan for Otsuka Pharmaceutical Factory’s Infusion Solution on July 15
July 3, 2020
- LDP Generic Study Group Urges Govt to Restructure Drug Supply Chain
July 1, 2020
- LDP Study Group Calls for Budgets to Accelerate Genome Analysis Project
July 1, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
- Japan Approval for MSD’s 9-Valent HPV Vaccine Delayed into July
June 30, 2020
- Japan Approves Entresto, 4 Other Novartis Meds, Rybelsus, 1st Humira Biosimilar and More
June 30, 2020
- 418 Key Drug Candidates Listed by 36 Societies, Panel to Outline Stable Supply Measures at Next Meeting
June 29, 2020
- PMDA Reviewing Safety Risk for 10 Contrast Agents
June 29, 2020
- LDP’s Coronavirus Task Force Calls for Caution in Off-Year Re-Pricing Debate
June 26, 2020
- Keidanren Chief Cited Industry’s Concerns about Off-Year Re-Pricing at CEFP Confab, Minutes Reveal
June 26, 2020
- Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
June 26, 2020
- MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
June 26, 2020
- Ruling Party Members Mull Govt’s Stronger Control Functions for Infectious Diseases, with Future COVID-19 Measures in Mind
June 26, 2020
- AMED to Allocate 6.2 Billion Yen to BIKEN’s COVID-19 Vaccine Project: CiCLE Program
June 25, 2020
- AMED to Fund 29 New Research Projects to Develop COVID-19 Treatments, including 5 Company-Led Projects
June 24, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…